Lewis Eldrin F
Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA,
Curr Treat Options Cardiovasc Med. 2011 Feb;13(1):79-89. doi: 10.1007/s11936-010-0100-y.
I individualize my approach to each patient based upon their understanding of their disease process, acuity of their progression to Stage D heart failure, clinical setting (hospitalized vs outpatient), and family needs. My first goal is to prove intolerance of traditional therapies for heart failure by challenging patients with various medication combinations, including staggered dosing regimens and alternatives to angiotensin-converting enzyme inhibitors/β-blockers, and by considering cardiac resynchronization therapy if they meet criteria. As patients develop progressive hypotension and side effects from medicines, I often will discontinue these medicines after careful communication. For patients with refractory heart failure, I consider cardiac transplantation for those who are candidates and left ventricular assist device as destination therapy for those who are not transplant candidates, both of which require multidisciplinary input from psychiatrists, social workers, nurses, and cardiac surgeons. If patients are not candidates for these advanced therapies, I try to delineate their goals for living and discuss strategies to maximize their survival (however limited) and increase my focus on their quality of life by minimizing unnecessary testing. For the select patient, I use continuous inotrope support only if this improves their quality of life and possibility of having a meaningful existence outside of the hospital. Palliative care consultants are often involved at this stage. For the patient who is clearly at the end of life, I refer to hospice and focus on comfort. Return ambulatory visits and extent of the care received are guided by the preferences of the patient and their family. When there are disparate views of family members, especially when the patient is not cognitively able to participate in the discussion, I tend to be more paternalistic in my approach to therapeutic options in an attempt to possibly dissipate family dynamic problems occurring after the patient dies.
我会根据每位患者对自身疾病进程的理解、进展至D期心力衰竭的严重程度、临床情况(住院还是门诊)以及家庭需求,为其制定个性化的治疗方案。我的首要目标是,通过让患者尝试各种药物组合(包括交错给药方案以及血管紧张素转换酶抑制剂/β受体阻滞剂的替代药物),并在患者符合标准时考虑心脏再同步治疗,来证明其对传统心力衰竭治疗不耐受。随着患者出现进行性低血压和药物副作用,我通常会在仔细沟通后停用这些药物。对于难治性心力衰竭患者,我会考虑为符合条件的患者进行心脏移植,为不符合移植条件的患者采用左心室辅助装置作为终末期治疗,这两种治疗都需要精神科医生、社会工作者、护士和心脏外科医生的多学科参与。如果患者不符合这些高级治疗的条件,我会尝试明确他们的生活目标,并讨论策略以最大化他们的生存时间(无论多么有限),通过尽量减少不必要的检查来增加我对他们生活质量的关注。对于特定患者,只有在持续使用血管活性药物支持能改善其生活质量以及增加其院外有意义生活可能性的情况下,我才会使用。姑息治疗顾问通常会在这个阶段参与进来。对于明显处于生命末期的患者,我会转诊至临终关怀机构,并专注于缓解痛苦。复诊和所接受护理的程度由患者及其家人的偏好决定。当家庭成员意见不一致时,尤其是当患者无法认知参与讨论时,我在治疗方案选择上会更家长式一些,试图化解患者去世后可能出现的家庭矛盾。